Industry
Biotechnology
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Insights
August 19, 2024 | 12:00 pm
Portfolio Pulse from Benzinga Newsdesk
August 19, 2024 | 11:25 am
Portfolio Pulse from Benzinga Insights
July 26, 2024 | 6:01 pm
Portfolio Pulse from Benzinga Newsdesk
July 26, 2024 | 11:25 am
Portfolio Pulse from Benzinga Newsdesk
July 02, 2024 | 10:23 am
Portfolio Pulse from Benzinga Newsdesk
July 01, 2024 | 12:03 pm
Portfolio Pulse from Benzinga Newsdesk
June 18, 2024 | 4:56 pm
Portfolio Pulse from Benzinga Newsdesk
June 18, 2024 | 3:10 pm
Portfolio Pulse from Benzinga Newsdesk
June 18, 2024 | 2:44 pm
Portfolio Pulse from Benzinga Insights
June 18, 2024 | 1:00 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.